Publications by authors named "Lisa J T Smits"
Article Synopsis
- In the LADI trial, researchers found that extending adalimumab (ADA) dosing intervals was just as effective as standard dosing for Crohn's disease patients in remission.
- The study aimed to create a prediction model to identify patients who could successfully increase their dosing intervals based on trial data.
- Results showed that 60.6% of patients successfully extended their dosing, with certain factors (like smoking and prior surgeries) making success less likely; the model's effectiveness needs further external validation before clinical use.
Article Synopsis
- The study aimed to evaluate the cost-effectiveness of lengthening adalimumab dosing intervals for patients with Crohn's disease who are in stable remission, compared to the standard two-week interval.
- A total of 174 patients participated, with results showing no significant difference in overall quality of life and total costs between the extended interval and control groups, although medication costs were lower in the extended group.
- Increased dosing intervals were deemed cost-effective if the value of a quality-adjusted life year is below €53,960, suggesting that for higher valuations, the conventional dosing remains more favorable.
Background: Outpatient visits and laboratory assessments are routinely scheduled every 3 to 4 months in thiopurine-treated patients with inflammatory bowel disease (IBD) to timely detect thiopurine-related adverse events (AEs). AEs that require therapy adjustment beyond 12 months of treatment are rare.
Aim And Methods: This single-center prospective cohort study evaluated the safety of a reduced 6-monthly monitoring strategy in steroid-free patients with quiescent IBD on stable dose of azathioprine, mercaptopurine, or thioguanine monotherapy.
Article Synopsis
- The LADI study investigated the effects of extending adalimumab dosing intervals in stable Crohn's disease patients compared to conventional 2-week dosing, focusing on clinical outcomes and the risk of infections.
- Patients in the intervention group increased their dosing to every 3 weeks and then possibly to every 4 weeks, while the control group maintained the 2-week schedule.
- The primary measure of effectiveness was the incidence of persistent disease flare-ups over 48 weeks, with a specific non-inferiority margin of 15% for comparing outcomes.
Article Synopsis
- - The study investigated the success rates and frequency of reducing biological therapy doses in patients with inflammatory bowel disease (IBD) after they had previously increased their doses.
- - Out of 346 patients who escalated their therapy, 34% (IFX), 21% (ADA), and 15% (VEDO) underwent de-escalation, with high success rates: 88% for IFX, 89% for ADA, and 100% for VEDO.
- - Successful de-escalation was more likely when guided by disease activity measures, with a success rate of 97%, compared to 76% when based on pharmacokinetic assessments, indicating that objective evaluations of disease remission can enhance
Background: Patients suffering from inflammatory bowel diseases (IBD) and treated with originator infliximab are increasingly being switched to biosimilars. Some patients, however, are "reverse switched" to treatment with the originator. Here we assess the prevalence of reverse switching, including its indication and outcomes.
View Article and Find Full Text PDFBackground: The infliximab biosimilar has entered daily inflammatory bowel disease (IBD) practice. However, real-life outcomes beyond 1 year after switching are scarce. We aimed to investigate the long-term drug survival, immunogenicity, and pharmacokinetics 2 years after switching to CT-P13 in IBD patients.
View Article and Find Full Text PDFBackground: Anti-TNF inhibitors successfully improve the quality of life of patients with inflammatory disease. Unfortunately, not all patients respond to anti-TNF therapy, and some patients show paradoxical immune side effects, which are poorly understood. Surprisingly, anti-TNF agents were shown to promote IL-17A production with as yet unknown clinical implications.
View Article and Find Full Text PDFBackground: Limited data are available on long-term clinical outcomes regarding the switch from Remicade to the infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD) patients.
Aims: To investigate long-term efficacy, safety, pharmacokinetic profile, and immunogenicity.
Methods: We performed a single-center prospective observational cohort study following an elective switch from Remicade to CT-P13 in IBD patients.
Background And Aims: The biosimilar of Remicade®, CT-P13, recently entered the European market. Clinical data on switching from Remicade® to CT-P13 in inflammatory bowel disease [IBD] are scarce. We aimed to prospectively investigate efficacy, safety, pharmacokinetic profile, and immunogenicity following a switch from Remicade® to CT-P13 in IBD patients.
View Article and Find Full Text PDFColorectal Cancer Risk in Patients With Lynch Syndrome and Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol
March 2017
Lynch syndrome and inflammatory bowel diseases (IBD) are associated with an increased risk of colorectal cancer (CRC). However, it is not clear whether the risk of CRC is even higher for patients with a combination of Lynch syndrome and IBD. We investigated the risk for CRC in this subgroup by establishing a Lynch syndrome cohort from the Radboud University Medical Center (Nijmegen, The Netherlands) and the Academic Medical Center (Amsterdam, The Netherlands).
View Article and Find Full Text PDFBackground & Aims: Colorectal neoplasia can still develop after colectomy for inflammatory bowel disease. However, data on this risk are scare, and there have been few conclusive findings, so no evidence-based recommendations have been made for postoperative surveillance. We conducted a systematic review and meta-analysis to determine the prevalence and incidence of and risk factors for neoplasia in patients with inflammatory bowel disease who have undergone colectomy, including the permanent-end ileostomy and rectal stump, ileorectal anastomosis (IRA), and ileal pouch-anal anastomosis (IPAA) procedures.
View Article and Find Full Text PDF